Kell antigen system
Kell Antigen System[edit | edit source]
The Kell antigen system is a complex blood group system that encompasses a variety of antigens on the red blood cell surface, with the K and k antigens being the most significant. This system plays a crucial role in blood transfusions and has important implications in obstetrics, particularly in cases of hemolytic disease of the fetus and newborn (HDFN).
Genetics[edit | edit source]
The Kell antigens are encoded by the KEL gene located on chromosome 7. The system is highly polymorphic, with more than 35 antigens identified, but the most clinically significant are K (Kell) and k (Cellano). The presence or absence of these antigens is determined genetically, with K being less common than k.
Antigens[edit | edit source]
The primary antigens within the Kell system, K and k, differ by a single amino acid on the Kell glycoprotein. The K antigen is relatively rare (present in about 9% of the Caucasian population and less frequently in other populations), making the k antigen much more common. Other notable antigens in the system include Kpa, Kpb, and Jsa.
Clinical Significance[edit | edit source]
- Blood Transfusion
The Kell antigen system is of paramount importance in blood transfusion medicine. Individuals who lack a specific Kell antigen can develop antibodies against that antigen if exposed to it through blood transfusion or pregnancy. These antibodies can cause transfusion reactions and hemolytic disease of the fetus and newborn (HDFN).
- Hemolytic Disease of the Fetus and Newborn (HDFN)
HDFN occurs when there is an incompatibility between the Kell antigens of the mother and fetus. A Kell-negative mother can produce anti-Kell antibodies if exposed to Kell-positive fetal red blood cells, potentially leading to fetal anemia, hydrops fetalis, and even fetal death.
Diagnosis[edit | edit source]
Diagnosis of Kell antigen compatibility is performed through blood typing and antibody screening. In pregnant women, the detection of anti-Kell antibodies is crucial for the management and treatment of HDFN.
Management[edit | edit source]
- Blood Transfusion
For patients requiring blood transfusion, compatibility testing includes screening for Kell antigens to prevent the formation of anti-Kell antibodies and avoid hemolytic transfusion reactions.
- Pregnancy
In cases of maternal anti-Kell antibodies, careful monitoring of the pregnancy is necessary, including ultrasound examinations to assess fetal well-being and, if necessary, intrauterine transfusions to treat fetal anemia.
Prevention[edit | edit source]
Preventing the formation of anti-Kell antibodies is challenging but can be managed by ensuring blood transfusion compatibility and monitoring at-risk pregnancies for signs of HDFN.
External Links[edit | edit source]
- National Center for Biotechnology Information - Blood Groups and Red Cell Antigens
- AABB - The Kell Blood Group System
References[edit | edit source]
Kell antigen system Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen